NASDAQ:INSMInsmed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.84 -0.13 (-0.46 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$27.39Now: $27.84▼$28.3250-Day Range$24.29MA: $27.14▼$29.5752-Week Range$12.09Now: $27.84▼$34.94Volume371,200 shsAverage Volume963,346 shsMarket Capitalization$2.81 billionP/E RatioN/ADividend YieldN/ABeta2.77 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.00, Insmed has a potential upside of 50.9% from its current price of $27.84.Amount of Analyst CoverageInsmed has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesInsmed has received 454 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInsmed has received 452 “underperform” votes. (Add your “underperform” vote.)Community SentimentInsmed has received 50.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote “Outperform” if you believe INSM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.63% of the stock of Insmed is held by insiders.Percentage Held by Institutions95.51% of the stock of Insmed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($2.65) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInsmed has a P/B Ratio of 9.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INSM Previous Symbol CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Debt Debt-to-Equity Ratio1.74 Current Ratio6.89 Quick Ratio6.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$136.47 million Price / Sales20.61 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book9.50Profitability EPS (Most Recent Fiscal Year)($3.01) Net Income$-254,340,000.00 Net Margins-162.82% Return on Equity-87.35% Return on Assets-33.04%Miscellaneous Employees373 Outstanding Shares101,040,000Market Cap$2.81 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:INSM Rates by TradingView Receive INSM News and Ratings via Email Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Insmed (NASDAQ:INSM) Frequently Asked Questions How has Insmed's stock been impacted by COVID-19 (Coronavirus)? Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INSM stock has increased by 31.0% and is now trading at $27.84. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Insmed? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Insmed. When is Insmed's next earnings date? Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insmed. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.02. The biopharmaceutical company had revenue of $36.90 million for the quarter, compared to the consensus estimate of $34.81 million. Insmed had a negative net margin of 162.82% and a negative return on equity of 87.35%. The business's revenue was up 68.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.96) EPS. View Insmed's earnings history. What price target have analysts set for INSM? 8 equities research analysts have issued 1-year price targets for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's share price to reach $42.00 in the next year. This suggests a possible upside of 50.9% from the stock's current price. View analysts' price targets for Insmed. Has Insmed been receiving favorable news coverage? Media stories about INSM stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insmed earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Insmed. Who are some of Insmed's key competitors? Some companies that are related to Insmed include Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Dr.Reddy's Laboratories (RDY), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE) and Reata Pharmaceuticals (RETA). View all competitors. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN). Who are Insmed's key executives? Insmed's management team includes the following people: Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)Mr. Paolo Tombesi, Chief Financial Officer (Age 55)Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)Mr. Roger Adsett, Chief Commercial Officer (Age 50)Dr. Paul D. Streck, Advisor (Age 55) What is Insmed's stock symbol? Insmed trades on the NASDAQ under the ticker symbol "INSM." Who are Insmed's major shareholders? Insmed's stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.02%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View institutional ownership trends for Insmed. Which major investors are buying Insmed stock? INSM stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis. View insider buying and selling activity for Insmed. How do I buy shares of Insmed? Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Insmed's stock price today? One share of INSM stock can currently be purchased for approximately $27.84. How big of a company is Insmed? Insmed has a market capitalization of $2.81 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe. What is Insmed's official website? The official website for Insmed is www.insmed.com. How can I contact Insmed? Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
